Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1

Status

Completed 25Terminated 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Pigmentation Disorders 1Neoplasms 1Keratosis, Actinic 1Hemangioma, Capillary 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has results × Imiquimod × Clear all
NCT02224599 2020-04-24

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

Kiromic BioPharma Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
Tumor-Agnostic

Neoplasms

NCT00979550 2018-03-22

The Effects of Aldara as an Adjunct to Laser Treatment

University of Kentucky

Phase 2 Terminated
7 enrolled 4 charts

Pigmentation Disorders, Hemangioma, Capillary

NCT01203878 2014-12-08

Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

Tennessee Clinical Research Center

Phase 4 Terminated
21 enrolled 10 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡